NantHealth (NASDAQ:NH) was upgraded by stock analysts at BidaskClub from a “sell” rating to a “hold” rating in a report released on Tuesday, March 6th.
Other analysts have also recently issued reports about the stock. Zacks Investment Research upgraded shares of NantHealth from a “hold” rating to a “buy” rating and set a $4.00 price target on the stock in a research note on Wednesday, November 22nd. Canaccord Genuity dropped their price target on shares of NantHealth from $6.00 to $5.00 and set a “buy” rating on the stock in a research note on Friday, November 17th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $8.05.
Shares of NantHealth (NASDAQ:NH) traded down $0.10 during mid-day trading on Tuesday, hitting $3.10. 186,714 shares of the company were exchanged, compared to its average volume of 133,082. The stock has a market cap of $343.40, a PE ratio of -2.08 and a beta of 0.64. The company has a quick ratio of 2.36, a current ratio of 2.38 and a debt-to-equity ratio of 0.93. NantHealth has a 12 month low of $2.60 and a 12 month high of $6.43.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Alliancebernstein L.P. purchased a new stake in NantHealth in the 2nd quarter worth approximately $102,000. Citadel Advisors LLC bought a new position in shares of NantHealth in the 4th quarter worth $103,000. Teachers Advisors LLC increased its holdings in shares of NantHealth by 351.8% in the 2nd quarter. Teachers Advisors LLC now owns 31,578 shares of the company’s stock worth $134,000 after buying an additional 24,588 shares during the last quarter. California State Teachers Retirement System increased its holdings in shares of NantHealth by 132.4% in the 2nd quarter. California State Teachers Retirement System now owns 31,600 shares of the company’s stock worth $134,000 after buying an additional 18,000 shares during the last quarter. Finally, Deutsche Bank AG increased its holdings in shares of NantHealth by 117.4% in the 4th quarter. Deutsche Bank AG now owns 45,610 shares of the company’s stock worth $137,000 after buying an additional 24,635 shares during the last quarter. Institutional investors and hedge funds own 6.27% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This piece was originally published by BBNS and is the property of of BBNS. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this piece can be viewed at https://baseballnewssource.com/2018/03/16/nanthealth-nh-lifted-to-hold-at-bidaskclub/1987960.html.
NantHealth Company Profile
NantHealth, Inc is a healthcare cloud-based information technology (IT) company. The Company is engaged in converging science and technology through a single integrated clinical platform, to provide actionable health information at the point of care. The Company offers the Genomic Proteomic Spectrometry (GPS) Cancer test, a molecular test and decision support solution that measures the proteins present in the patient’s tumor tissue, combined with whole genomic and transcriptomic sequencing of tumor and normal samples.
Receive News & Ratings for NantHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth and related companies with MarketBeat.com's FREE daily email newsletter.